Goldman Sachs Group Inc Bei Gene, Ltd. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 30,658 shares of BGNE stock, worth $5.41 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
30,658
Previous 81,126 62.21%
Holding current value
$5.41 Million
Previous $11.6 Million 40.53%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
SELL
$143.93 - $224.51 $7.26 Million - $11.3 Million
-50,468 Reduced 62.21%
30,658 $6.88 Million
Q2 2024

Aug 13, 2024
BUY
$129.52 - $174.32 $2.95 Million - $3.96 Million
22,741 Added 38.95%
81,126 $11.6 Million
Q1 2024

May 15, 2024
SELL
$141.8 - $181.47 $22.1 Million - $28.3 Million
-155,954 Reduced 72.76%
58,385 $9.13 Million
Q4 2023

Feb 13, 2024
BUY
$158.67 - $201.58 $21.7 Million - $27.5 Million
136,458 Added 175.21%
214,339 $38.7 Million
Q3 2023

May 14, 2024
SELL
$179.87 - $225.13 $24.5 Million - $30.7 Million
-136,458 Reduced 63.66%
77,881 $14 Million
Q3 2023

Nov 14, 2023
BUY
$179.87 - $225.13 $1.25 Million - $1.56 Million
6,935 Added 9.78%
77,881 $14 Million
Q2 2023

May 14, 2024
BUY
$178.3 - $266.78 $843,537 - $1.26 Million
4,731 Added 7.14%
70,946 $12.6 Million
Q2 2023

Aug 14, 2023
BUY
$178.3 - $266.78 $843,537 - $1.26 Million
4,731 Added 7.14%
70,946 $12.6 Million
Q1 2023

May 14, 2024
SELL
$215.53 - $274.5 $458,216 - $583,587
-2,126 Reduced 3.11%
66,215 $14.3 Million
Q1 2023

May 11, 2023
SELL
$215.53 - $274.5 $458,216 - $583,587
-2,126 Reduced 3.11%
66,215 $14.3 Million
Q4 2022

May 14, 2024
SELL
$125.51 - $229.3 $27.2 Million - $49.6 Million
-216,353 Reduced 75.99%
68,341 $15 Million
Q4 2022

Feb 13, 2023
SELL
$125.51 - $229.3 $27.2 Million - $49.6 Million
-216,353 Reduced 75.99%
68,341 $15 Million
Q3 2022

May 14, 2024
BUY
$131.8 - $202.24 $5.46 Million - $8.37 Million
41,401 Added 17.02%
284,694 $38.4 Million
Q3 2022

Nov 10, 2022
BUY
$131.8 - $202.24 $5.46 Million - $8.37 Million
41,401 Added 17.02%
284,694 $38.4 Million
Q2 2022

May 14, 2024
BUY
$121.11 - $216.05 $3.51 Million - $6.26 Million
28,954 Added 13.51%
243,293 $39.4 Million
Q2 2022

Aug 15, 2022
BUY
$121.11 - $216.05 $559,164 - $997,502
4,617 Added 1.93%
243,293 $39.4 Million
Q1 2022

May 16, 2022
BUY
$146.52 - $269.56 $7.36 Million - $13.5 Million
50,236 Added 26.66%
238,676 $45 Million
Q4 2021

Feb 14, 2022
BUY
$248.56 - $389.34 $6.14 Million - $9.62 Million
24,701 Added 15.09%
188,440 $51.1 Million
Q3 2021

Nov 10, 2021
BUY
$249.6 - $403.14 $40.9 Million - $66 Million
163,739 New
163,739 $59.4 Million

Others Institutions Holding BGNE

# of Institutions
252
Shares Held
45.3M
Call Options Held
292K
Put Options Held
119K
View Full List

About BeiGene, Ltd.

BGNE Quotes by TradingView
  • Ticker BGNE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,700,000
  • Market Cap $18.3B
  • Description
  • BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...
More about BGNE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email